<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930680</url>
  </required_header>
  <id_info>
    <org_study_id>2014006</org_study_id>
    <nct_id>NCT03930680</nct_id>
  </id_info>
  <brief_title>Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane</brief_title>
  <acronym>PHOENIX1</acronym>
  <official_title>Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Ming Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether early administration of
      Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study on volunteers to determine minimum effective dose of dexrazoxane in degrading
      Topoisomerase 2 b in human blood samples. Each participant will receive one lower than FDA
      approved dose of dexrazoxane. Blood samples will be collected to determine the time course
      and degradation of Topoisomerase 2b.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject will receive one dose of dexrazoxane.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degradation of Topoisomerase 2 b</measure>
    <time_frame>32 hours after administration</time_frame>
    <description>Topoisomerase 2 b degradation to less than 1% of baseline level in human blood of 5 volunteers.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>100mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of 100mg/m2 dexrazoxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of 200mg/m2 dexrazoxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of 300mg/m2 dexrazoxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of 400mg/m2 dexrazoxane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg/m2 or 500 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of either 50 mg/m2 or 500 mg/m2 dexrazoxane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane</intervention_name>
    <description>One lower than FDA approved dose of dexrazoxane</description>
    <arm_group_label>100mg/m2</arm_group_label>
    <arm_group_label>200mg/m2</arm_group_label>
    <arm_group_label>300 mg/m2</arm_group_label>
    <arm_group_label>400 mg/m2</arm_group_label>
    <arm_group_label>50mg/m2 or 500 mg/m2</arm_group_label>
    <other_name>Zinecard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women,

          -  Age 18-65,

          -  Not pregnant, Not currently breast feeding

          -  No current illness,

          -  Not on prescribed medication,or nutritional supplement

        Exclusion Criteria:

          -  Pregnancy, currently breast feeding

          -  Current illness,

          -  On prescribed medication or nutritional supplement

          -  History of cardiac, or renal disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Ming Chang, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Ming Chang, MD,MPH</last_name>
    <phone>573-882-8280</phone>
    <email>changhu@health.missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edward TH Yeh, MD</last_name>
    <phone>573-882-8280</phone>
  </overall_contact_backup>
  <reference>
    <citation>Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017 Nov 14;70(20):2536-2551. doi: 10.1016/j.jacc.2017.09.1096. Review. Erratum in: J Am Coll Cardiol. 2018 Feb 6;71(5):587.</citation>
    <PMID>29145954</PMID>
  </reference>
  <reference>
    <citation>Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov;18(11):1639-42. doi: 10.1038/nm.2919. Epub 2012 Oct 28.</citation>
    <PMID>23104132</PMID>
  </reference>
  <reference>
    <citation>Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 1;119(19):3555-62. doi: 10.1002/cncr.28256. Epub 2013 Jul 16.</citation>
    <PMID>23861158</PMID>
  </reference>
  <reference>
    <citation>Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984 Oct 26;226(4673):466-8.</citation>
    <PMID>6093249</PMID>
  </reference>
  <reference>
    <citation>Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003 Oct 15;63(20):6602-6.</citation>
    <PMID>14583452</PMID>
  </reference>
  <reference>
    <citation>Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol. 2003 Nov 10;163(3):477-87. Epub 2003 Nov 3.</citation>
    <PMID>14597774</PMID>
  </reference>
  <reference>
    <citation>Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007 Sep 15;67(18):8839-46.</citation>
    <PMID>17875725</PMID>
  </reference>
  <reference>
    <citation>Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997 Apr;15(4):1318-32.</citation>
    <PMID>9193323</PMID>
  </reference>
  <reference>
    <citation>Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the &quot;Silver Tsunami&quot;: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36. doi: 10.1158/1055-9965.EPI-16-0133.</citation>
    <PMID>27371756</PMID>
  </reference>
  <reference>
    <citation>Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017 Nov 14;70(20):2552-2565. doi: 10.1016/j.jacc.2017.09.1095. Review.</citation>
    <PMID>29145955</PMID>
  </reference>
  <reference>
    <citation>Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL, Oeffinger KC. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014 Apr 20;32(12):1218-27. doi: 10.1200/JCO.2013.51.1055. Epub 2014 Mar 17.</citation>
    <PMID>24638000</PMID>
  </reference>
  <reference>
    <citation>Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ET, Shore RE. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656-65. doi: 10.1016/j.ijrobp.2009.09.064. Review.</citation>
    <PMID>20159360</PMID>
  </reference>
  <reference>
    <citation>Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 2004 Jan;130(1):1-7. Epub 2003 Oct 17. Review.</citation>
    <PMID>14564513</PMID>
  </reference>
  <reference>
    <citation>Yeh ET, Chang HM. Oncocardiology-Past, Present, and Future: A Review. JAMA Cardiol. 2016 Dec 1;1(9):1066-1072. doi: 10.1001/jamacardio.2016.2132.</citation>
    <PMID>27541948</PMID>
  </reference>
  <reference>
    <citation>Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333-53.</citation>
    <PMID>4290058</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710-7.</citation>
    <PMID>496103</PMID>
  </reference>
  <reference>
    <citation>Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983 Feb;43(2):460-72.</citation>
    <PMID>6293697</PMID>
  </reference>
  <reference>
    <citation>Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980 Jan;65(1):128-35.</citation>
    <PMID>7350193</PMID>
  </reference>
  <reference>
    <citation>Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991 Mar 21;324(12):843-5.</citation>
    <PMID>1997858</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008 Aug 1;26(22):3777-84. doi: 10.1200/JCO.2007.14.9401.</citation>
    <PMID>18669466</PMID>
  </reference>
  <reference>
    <citation>Herman EH, Ferrans VJ, Myers CE, Van Vleet JF. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. 1985 Jan;45(1):276-81.</citation>
    <PMID>3917371</PMID>
  </reference>
  <reference>
    <citation>Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983 Mar;10(1 Suppl 1):53-5.</citation>
    <PMID>6340204</PMID>
  </reference>
  <reference>
    <citation>Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009 Jan 8;255(1-2):72-9. doi: 10.1016/j.tox.2008.10.011. Epub 2008 Oct 25.</citation>
    <PMID>19010377</PMID>
  </reference>
  <reference>
    <citation>Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992 Aug 17;1132(1):43-8.</citation>
    <PMID>1380833</PMID>
  </reference>
  <reference>
    <citation>Wang J, Zhang S, Rabinovich B, Bidaut L, Soghomonyan S, Alauddin MM, Bankson JA, Shpall E, Willerson JT, Gelovani JG, Yeh ET. Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. Circ Res. 2010 Jun 25;106(12):1904-11. doi: 10.1161/CIRCRESAHA.110.221762. Epub 2010 May 6.</citation>
    <PMID>20448213</PMID>
  </reference>
  <reference>
    <citation>Hasinoff BB. Chemistry of dexrazoxane and analogues. Semin Oncol. 1998 Aug;25(4 Suppl 10):3-9.</citation>
    <PMID>9768817</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Hui-Ming Chang</investigator_full_name>
    <investigator_title>Co-Director, Center for Precision Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

